These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18841437)

  • 1. Oral administration of cilnidipine to patients with hypertensive intracerebral hemorrhage in the acute stage: significance and role of an N-type calcium channel blocker.
    Matsuno A; Ide F; Tanaka H; Asano S; Miyawaki S; Uno T; Tanaka J; Nakaguchi H; Sasaki M; Murakami M; Fuke N
    Ir J Med Sci; 2009 Dec; 178(4):419-22. PubMed ID: 18841437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE.
    Kario K; Ando S; Kido H; Nariyama J; Takiuchi S; Yagi T; Shimizu T; Eguchi K; Ohno M; Kinoshita O; Yamada T
    J Clin Hypertens (Greenwich); 2013 Feb; 15(2):133-42. PubMed ID: 23339732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine.
    Seino H; Miyaguchi S; Yamazaki T; Ota S; Yabe R; Suzuki S
    Arzneimittelforschung; 2007; 57(8):526-31. PubMed ID: 17915639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.
    Masaki M; Mano T; Eguchi A; Fujiwara S; Sugahara M; Hirotani S; Tsujino T; Komamura K; Koshiba M; Masuyama T
    Heart Vessels; 2016 Nov; 31(11):1826-1833. PubMed ID: 26825736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between L-type and N/L-type calcium channel blockers in the regulation of home blood-pressure variability in elderly hypertensive patients.
    Nozato S; Yamamoto K; Nozato Y; Takeda M; Hongyo K; Takeya M; Akasaka H; Takami Y; Takeya Y; Sugimoto K; Ito N; Rakugi H
    Hypertens Res; 2018 Apr; 41(4):290-298. PubMed ID: 29449705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage: a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study).
    Koga M; Toyoda K; Yamagami H; Okuda S; Okada Y; Kimura K; Shiokawa Y; Nakagawara J; Furui E; Hasegawa Y; Kario K; Osaki M; Miyagi T; Endo K; Nagatsuka K; Minematsu K;
    J Hypertens; 2012 Dec; 30(12):2357-64. PubMed ID: 22990355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antihypertensive effects of repeated oral administration of cilnidipine, a novel calcium antagonist, in 2K1C renal hypertensive dogs].
    Takahara A; Uchida H; Konda T; Dohmoto H; Yoshimoto R; Komori M; Morioka T; Ono I; Takata Y; Kato H
    Nihon Yakurigaku Zasshi; 1995 Oct; 106(4):279-87. PubMed ID: 8537075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous nicardipine dosing for blood pressure lowering in acute intracerebral hemorrhage: the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study.
    Koga M; Arihiro S; Hasegawa Y; Shiokawa Y; Okada Y; Kimura K; Furui E; Nakagawara J; Yamagami H; Kario K; Okuda S; Tokunaga K; Takizawa H; Takasugi J; Sato S; Nagatsuka K; Minematsu K; Toyoda K;
    J Stroke Cerebrovasc Dis; 2014; 23(10):2780-2787. PubMed ID: 25314943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N- and L-type calcium channels blocker cilnidipine ameliorates neuropathic pain.
    Yamamoto S; Suzuki Y; Ono H; Kume K; Ohsawa M
    Eur J Pharmacol; 2016 Dec; 793():66-75. PubMed ID: 27823932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients.
    Ito T; Fujimoto N; Ishikawa E; Dohi K; Fujimoto M; Murata T; Kiyohara M; Takeuchi H; Koyabu S; Nishimura H; Takeuchi T; Ito M
    Clin Exp Hypertens; 2019; 41(1):92-99. PubMed ID: 29584458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
    Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
    Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.
    Takashima K; Nishiyama C; Arisaka N; Takahashi T; Souma S; Tsuda M; Hayashi M; Kasahara H; Kodama H; Tamura T; Murakami M; Kuroda J; Sato F
    Arzneimittelforschung; 2009; 59(2):79-85. PubMed ID: 19338138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine.
    Sugiyama A; Satoh Y; Takahara A; Ando K; Nakamura Y; Hashimoto K
    Heart Vessels; 2005 May; 20(3):112-5. PubMed ID: 15912307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive activity of a new calcium channel blocker LF 2.0254, in spontaneously hypertensive rats: a comparison with nifedipine and nicardipine.
    Pruneau D; Brown NL
    Arch Int Pharmacodyn Ther; 1988; 295():109-24. PubMed ID: 2977540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
    Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
    Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of haemodynamic responses to cilnidipine and nicardipine in an experimental model of acute congestive heart failure.
    Noguchi K; Matsuzaki T; Koyama T; Itomine T; Sakanashi M
    Clin Exp Pharmacol Physiol; 1998; 25(7-8):541-7. PubMed ID: 9673425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of an L/N-type Ca2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs.
    Takahara A; Sugiyama A; Satoh Y; Nakamura Y; Hashimoto K
    J Pharmacol Sci; 2004 Oct; 96(2):219-23. PubMed ID: 15492462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.